Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.230
-0.260-3.06%
Volume:174.56M
Turnover:1.45B
Market Cap:94.83B
PE:22.32
High:8.720
Open:8.410
Low:7.990
Close:8.490
52wk High:11.454
52wk Low:4.463
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:4.20
T/O Rate:1.52%
Dividend:0.24
Dividend Rate:2.91%
EPS(LYR):0.369
ROE:10.83%
ROA:5.65%
PB:2.52
PE(LYR):22.32
PS:3.19

Loading ...

CSPC Pharmaceutical - Nintedanib Esilate Powder Approved for Clinical Trials in China

THOMSON REUTERS
·
Jan 02

CSPC Pharmaceutical Group Stock Slides 0.8% in Hong Kong

Dow Jones
·
Dec 30, 2025

Novo and Lilly cut prices of weight-loss drugs in China

Reuters
·
Dec 29, 2025

Novo cuts Wegovy prices in some Chinese provinces, local media reports

Reuters
·
Dec 29, 2025

CSPC Wins China Clinical Trial Approval for SYH2072 Aldosterone Synthase Inhibitor

Reuters
·
Dec 29, 2025

CSPC PHARMA (01093): GLP-1/GIP Receptor Dual-Biased Agonist Polypeptide Injection (SYH2069 Injection) Receives Clinical Trial Approval in China

Stock News
·
Dec 29, 2025

BRIEF-Cspc Pharmaceutical Says Prusogliptin, Dapagliflozin And Metformin Extended-Release Tablets Get Clinical Trial Approval In China

Reuters
·
Dec 29, 2025

CSPC Pharmaceutical Wins China Clinical Trial Nod for Triple Diabetes Drug

Reuters
·
Dec 29, 2025

CSPC Pharmaceutical - Prusogliptin, Dapagliflozin and Metformin Extended-Release Tablets Obtain Clinical Trial Approval in China

THOMSON REUTERS
·
Dec 29, 2025

CSPC Pharmaceutical - Glp-1/Gip Receptor Dual-Biased Agonist Polypeptide Injection (Syh2069 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Dec 29, 2025

CSPC Pharmaceutical Wins China Clinical Trial Nod for GLP-1/GIP Dual Agonist Injection

Reuters
·
Dec 29, 2025

CSPC Pharmaceutical Group Stock Sheds 2.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Dec 29, 2025

Active Southbound Stock Connect Trading on Dec 24, 2025

Stock News
·
Dec 24, 2025

CSPC Pharma's Next-Gen Leadership Takes Over with $450 Million Bet on Weight-Loss Sector

Deep News
·
Dec 24, 2025

CSPC Pharmaceutical Group Stock Falls 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Dec 24, 2025

CSPC Pharma Establishes New Subsidiary with 450 Million Yuan Investment

Deep News
·
Dec 23, 2025

CSPC Pharma Gets China Nod for Multiple Myeloma Drug Trial

MT Newswires Live
·
Dec 23, 2025

BRIEF-Cspc Pharmaceutical Announces Approval For Daratumumab Injection In China

Reuters
·
Dec 23, 2025

CSPC Pharmaceutical Group Wins Approval to Begin Daratumumab Biosimilar Trials in China

Reuters
·
Dec 23, 2025

CSPC Pharmaceutical - Announces Approval for Daratumumab Injection in China

THOMSON REUTERS
·
Dec 23, 2025